Delcath Systems, Inc. reported total revenue of $24.2 million for the second quarter ended June 30, 2025, a substantial increase from $7.8 million in the same period of the prior year. U.S. sales of HEPZATO KIT contributed $22.5 million, while CHEMOSAT sales in Europe accounted for $1.7 million.
The company reported a net income of $2.7 million for the quarter, a significant improvement from a net loss of $13.7 million in Q2 2024. Non-GAAP adjusted EBITDA also saw strong growth, reaching $9.8 million compared to a loss of $0.8 million in the prior year.
As of June 30, 2025, Delcath held $81.0 million in cash and investments and remained debt-free. The company reaffirmed its full year 2025 total revenue guidance of $94 to $98 million, indicating confidence in continued commercial momentum and growth prospects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.